Genor Biopharma (HKG:6998) said breast cancer drug Lerociclib was included in China's updated National Reimbursement Drug List for the first time, a Monday Hong Kong bourse filing said.
Shares of the firm were down nearly 2% in Tuesday afternoon trading.
The new edition of the list will become effective Jan. 1, 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments